OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)
BIOGRAPHICAL SKETCH

NAME: Rutherford, Thomas J.
POSITION TITLE: Medical Director of Tampa General Hospital Cancer Center, Division Director of Gynecologic Oncology
EDUCATION/TRAINING
INSTITUTION AND LOCATION
Roanoke College B.S. 1976 Chemistry
State University of New York at Buffalo
N.A.
1977
John Carroll University
Medical College of Ohio at Toledo
Medical College of Ohio at Toledo
M.S.
Ph.D.
M.D.
1983
1986
1989
Chemistry
Molecular Biology
General Surgery Internship and Residency
A. Personal Statement
Dr. Thomas J. Rutherford, M.D., has been the Director of Oncology for South Florida University in Tampa, FL, since January 2017. Dr. Rutherford serves as Chair of Gynecological Oncology at Yale University Medical School. Dr. Rutherford is a highly renowned and respected oncologist and a national expert in cancer, with more than 30 years of highly specialized surgical and clinical expertise in gynecologic cancer care. Dr. Rutherford has published in excess of 200 articles and case reports during his career and is a highly sought after speaker and lecturer. Prior, from January 2015 through December 2016, he was the Director of Oncology for Connecticut Oncology, a Division of Women’s Health of Connecticut and Director of Cancer Services for Western Connecticut Health Network leading more than 100 physician subspecialists including surgeons, medical oncologists and radiation oncologists. He serves as Director of Grom Social Enterprises, Inc. He serves as Independent Director at Grom Social, Inc. Dr. Rutherford served as Director of Illumination America, Inc. since January 11, 2017. He has served as a director of Grom Holdings, Inc. since July 2015. He served as a Member of Strategic Advisory Board at Mira Dx, Inc. Dr. Rutherford practiced at Yale Oncology and served as Professor of Oncology and Director of Oncology Fellowship at Yale University School of Medicine from July 1993 through December 2014. Dr. Rutherford received a Bachelor of Science degree in 1976 from Roanoke College, a Master of Science degree from John Carroll University in 1979 and a PhD from the Medical College of Ohio in 1989.
B. Positions and Honors
Positions and Employment
1/17 – present University of South Florida Morsani College of Medicine
Division Director of Gynecology Oncology
Tampa, FL
1/17 – present Tampa General Hospital
Medical Director of Cancer Center
Tampa, FL
7/15 – 1/17 University of Vermont College of Medicine
Clinical Professor in the Volunteer Pathway
Burlington, VT
1/15 – 1/17 Director of Gynecologic Oncology
CT Gynecologic Oncology
Avon, CT
1/15 – 1/17 Director of Western CT Health Network Cancer Center
Director of Gynecologic Oncology
Danbury, CT
6/11 – 1/15 Yale University School of Medicine
New Haven, CT
Professor – Gynecologic Oncology
11/11 – 6/14 Yale University School of Medicine
New Haven, CT
Interim Division Director of UroGynecology
10/05 – 6/14 Yale University School of Medicine
New Haven, CT
Division Director – Gynecologic Oncology
2/04 – 1/15 Yale University School of Medicine
New Haven, CT
Director of Gynecologic Oncology Fellowship
6/00 – 6/2011 Yale University School of Medicine
New Haven, CT
Associate Professor - Gynecologic Oncology
7/95 - 6/00 Yale University Medical School
New Haven, CT
Assistant Professor - Gynecologic Oncology
7/93 - 6/95 Yale University Medical School
New Haven, CT
Gynecologic Oncology Fellowship
12/90 - 6/93 Cooper Hospital/University Medical Center
Robert Wood Johnson Medical School
Camden, NJ
Residency in Obstetric and Gynecology
1/92 - 2/92 Memorial Sloan Kettering Hospital
New York, NY
Galloway Fellowship
6/89 - 11/90 Albert Einstein Medical Center
Philadelphia, PA
Residency in Obstetric and Gynecology
9/86 - 2/89 Medical College of Ohio at Toledo
Toledo, OH
Research Assistant, Pediatric Department
1/85 - 9/86 Medical College of Ohio at Toledo
Toledo, OH
Post-Doctoral Fellowship, Surgery Department
12/82 - 5/89 Toledo Hospital, Toledo, OH - Clinical Chemist
5/75 - 9/81 Rutherford Brothers Construction Co.
Hatfield, PA
Licensure and Certifications
2017 – Present FL #ME130333
NJ #56890 (inactive)
PA #046132 L (inactive)
2016 – Present DEA #BR 3384409
11/97 Ob/Gyn Diplomat
4/00 Gyn/Oncology- Board Certified
08/15 Re-certification completed
Other Experience and Professional Memberships
American Medical Association
SGO Finance Committee
International Society for the Study of Trophoblastic Disease
Reviewer, State of CT, Department of Public Health
Director of Gynecologic Fellowship
Madison Who’s Who
Awards and Honors
1/94 - 6/95 American Cancer Clinical Oncology Fellowship
Alpha Omega Alpha, Honor Medical Society
Tau Sigma Rho Mathematics Honorary Society
Phi Delta Epsilon Medical Fraternity
Pi Kappa Phi Fraternity, President 1976
American College of Ob/Gyn
Society of Gynecologic Oncologists
New England Association of Gynecologic Oncologists
1995 1995 New England Association Gynecologic Oncologists Trainee Award
5/96 -present American Medical Association
5/96 Cigna Oncology Steering Committee
8/96 Anthem BC/BS Oncology Panel
5/98 –5/04 SGO Government Relations Committee
2000 Strathmore’s Who’s Who
1/01 -present SGO Finance Committee
6/01 -present International Society for the Study of Trophoblastic Disease
2/02 -present Reviewer, State of CT, Department of Public Health
1/02 –1/05 SGO Coding Committees
6/02 Guide to Americas Top Obstetricians and Gynecologist
2/04 –present Director of Gynecologic Fellowship
8/04 –present Madison Who’s Who
10/05 –2014 Division Director of Gynecologic Oncology
1/10 – 2/5/15 Consultant – Gastrointestinal Drugs Advisory Committee, FDA
9/25/2013 Sanqin Friendship Award – Shaanxi Province
6/2014 Top Doctors – Castle Connolly Medical LTD.
C. Contributions to Science
Recent publications of importance to the field (in chronological order selected from 43 peer-reviewed publications)
• Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology. 145(1) : 122-129, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28190649
• von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecologic oncology. 144(3) : 459-467, 2017. http://www.ncbi.nlm.nih.gov/pubmed/28089376
• Black JD, Roque DM, Pasternak MC, Buza N, Rutherford TJ, Schwartz PE, McCarthy S, Ratner E. A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 25(5) : 792-7, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25790042
• English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 121(3) : 403-12, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25251053
• Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & experimental metastasis. 32(1) : 29-38, 2015. http://www.ncbi.nlm.nih.gov/pubmed/25398397
• Uma Deshmukh, U, Black, J, Perez-Irizarry, J, Passarelli, R, Levy, k, Rostkowski, A, Hui, P, Rutherford, T J, Santin, A D, Azodi, M, Silasi, D A, Ratner, E, Litkouhi, B, Schwartz, P E. (2018) Adjuvant hormal therapy for low-grade stromal sarcoma. Repro Sci Vol 26, 5:600-608.
• Randall, M.E., Filiaci, V, McMeekin, S, von Gruenigen, V, Huang, H, Yashar, C.M., Mannel, R,S, Kim, J,W, Salani, R, DiSilvestro, P,A, Burke, J, J, Rutherford, T, Spirtos, N,M, Terada, K, Anderson, P, R, Brewster, W,R, Small, W, Aghajanian, C,A, Miller,D,S. (2019) Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus Paclitaxel/Carboplatin in high-intermediate and high-risk early stage endometrial cancer. JCO https://ascopubs.org/doi/abs/10.1200/JCO.18.01575.
D. Research Support
Most Relevant Research Support
A study of Phenoxodiol in patients with recurrent ovarian, fallopian and primary peritoneal cancer that is resistant to second line chemotherapy
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol
(Intravenous Dosage Form and Oral Dosage Form) as a Chemo-Sensitizing Agent for
Cisplatin, Carboplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer that is Platinum- and/or Taxane-Refractory or Resistant
Principal Investigator: Thomas Rutherford, M.D., Ph.D.
Study Sponsor: Marshall Edwards Pty Limited $837,545.00
A Placebo-Controlled Phase Ib/IIa Safety, Tolerability and Efficacy Study of Oral Phenoxodiol in Combination with Docetaxel versus Docetaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing
Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy
Principal Investigator: Thomas J. Rutherford, M.D.
Study Sponsor: Marshall Edwards Pty Limited $554,775.00
PT-301, A Non-Interventional Prospective Study of the Accuracy of the Precision Therapeutics, Inc.
ChemoResponse Assay in Patients with Recurrent epithelial ovarian, Peritoneal or
fallopian tube cancer
Principal Investigator: Thomas J. Rutherford, MD, PhD
Study Sponsor: Precision Therapeutics, Inc. $93,600.00
Protocol AF4095g:
A Phase II, Multicenter, Randomized, Blinded Placebo-Controlled Trial of
Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma
Principal Investigator: Thomas J. Rutherford M.D.
Study Sponsor: Genentech, Inc.
Ovature Trial:
A Multi-Center, Multi-National, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatinum with Placebo in Patients with Platinum-resistant or Platinum refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Platinum Therapy
Principal Investigator: Thomas J. Rutherford, M.D., Ph.D.
Study Sponsor: Marshall Edwards Pty Limited
A Phase II Study of AP23573:
A mTOR inhibitor, in female Adult Patients with recurrent of persistent endometrial cancer
CO-Investigator: Thomas J. Rutherford, M.D.
Study Sponsor: ARIAD Pharmaceuticals, Inc.
MyD88 bearing tumors in immune regulation and chemo-resistance;
ID#: R01-CA127913
Principle Investigator: Gil Mor M.D.
Co-Investigator: Thomas J Rutherford M.D., Ph.D.
Study Sponsor NCI: 2008 – 2013
Total Cost $2,068,021 Direct Cost per year $250,000
Apoptosis and cancer
NCI; ID# R01 CA97237-01
Principle Investigator: Gil Mor M.D.
Co-Investigator: Thomas J. Rutherford Ph.D., M.D.
Study Sponsor NCI: 2007 – 2012
Total Cost $1,571,380 Direct Cost per year $190,000
Ovarian cancer prevention and early detection program
ID#: 1H75DP001824-01
Principle Investigator: Thomas J Rutherford Ph.D., M.D.
Study Sponsor: CDC; National Center for Chronic Disease Prevention and Health
Promotion
Total Cost $286,899.00